China SXT Pharmaceuticals, Inc. Announces Share Consolidation
Rhea-AI Summary
China SXT Pharmaceuticals (Nasdaq: SXTC) will effect a 1-for-150 share consolidation of its Class A ordinary shares, effective February 3, 2026. The company expects Class A shares to trade on Nasdaq under SXTC with new CUSIP G2161P165 at market open on that date.
Prior to consolidation 143,693,892 Class A shares were outstanding; after consolidation approximately 957,960 shares are expected. Fractional shares will be rounded up. Outstanding options, warrants and purchase rights will be adjusted proportionately. Shareholders holding shares through brokers will see automatic adjustments; contact Transhare Corporation for transfer-agent support.
Positive
- Share count reduced from 143,693,892 to ~957,960 shares
- Post-consolidation trading continues on Nasdaq under the same ticker SXTC
Negative
- Fractional shares rounded up, slightly increasing post-consolidation share count
- Outstanding options and warrants will be adjusted, creating administrative complexity
News Market Reaction
On the day this news was published, SXTC declined 38.00%, reflecting a significant negative market reaction. Argus tracked a peak move of +5.8% during that session. Argus tracked a trough of -48.1% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $6M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SXTC’s pre-news weakness contrasted with mixed peer moves: DERM and IRWD were modestly higher (1.08%, 1.67%), while OGI, TKNO, and BIOA were down between 2–3%. No peers appeared in the momentum scanner, pointing to a stock-specific setup ahead of the share consolidation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 15 | AI initiative | Positive | +10.2% | Announced AI Insight Initiative for TCM raw-material supply chain optimization. |
| Jan 09 | Capital raising | Negative | -87.9% | Announced $10M registered direct offering at $0.15 per share with warrants. |
| Jan 08 | AI initiative | Positive | -37.5% | Launched strategic AI Insights Initiative for portfolio planning and AI clinics. |
Recent SXTC news has driven large, often negative price swings, with capital-raising activity on Jan 9 followed by a sharp selloff and mixed reactions to AI-related strategic announcements.
Over the past month, SXTC issued several material updates. On Jan 8 and Jan 15, the company announced AI-focused initiatives aimed at optimizing its TCM portfolio and supply chain, with one update followed by a 10.18% gain and the other by a 37.5% decline. On Jan 9, a $10 million registered direct offering coincided with an 87.92% drop. Today’s share consolidation follows this dilution and steep price erosion.
Regulatory & Risk Context
SXTC has an effective Form F-3 shelf filed on Nov 10, 2025, allowing it to offer up to $600,000,000 in various securities. The shelf has already been used once via a 424B5 offering on Jan 12, 2026, underscoring an established mechanism for additional capital raises.
Market Pulse Summary
The stock dropped -38.0% in the session following this news. A negative reaction despite the mechanical nature of a 1-for-150 share consolidation would fit SXTC’s recent pattern of sharp declines around structural changes, including the 87.92% drop after the January 9 offering. Pre-news, the stock traded at $0.05, far below the $7.84 52-week high. The consolidation follows heavy dilution under an active $600,000,000 shelf, which may keep pressure on sentiment.
Key Terms
cusip number regulatory
stock options financial
warrants financial
transfer agent regulatory
AI-generated analysis. Not financial advice.
TAIZHOU, China, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the “Company” or “SXTC”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-150, effective on February 3, 2026 (the “Share Consolidation”). The Company’s Class A ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on February 3, 2026. Upon the market opening on February 3, 2026, the Company’s Class A ordinary shares will continue to be traded on The Nasdaq Stock Market under the symbol “SXTC” with the new CUSIP number G2161P165.
Prior to the Share Consolidation, 143,693,892 Class A ordinary shares are issued and outstanding. As a result of the Share Consolidation, every 150 shares (or part thereof) will be combined into one (1) share, with fractional shares rounded up to the next whole share, and approximately 957,960 Class ordinary shares will be issued and outstanding after the Share Consolidation. The Company is authorized to issue an unlimited number of shares, divided into two Classes consisting of: (i) Class A ordinary shares with no par value and (ii) Class B ordinary shares with no par value. All outstanding stock options, warrants and other rights to purchase the Company's Class A ordinary shares will be adjusted proportionately as a result of the Share Consolidation.
Upon the effectuation of the Share Consolidation, shareholders holding shares through a bank, broker or other nominee will have their shares automatically adjusted to reflect the Share Consolidation. Beneficial holders may contact their bank, broker or nominee for more information. Please direct any questions to your broker or the Company's transfer agent, Transhare Corporation, by calling +1 303-662-1122.
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.
Safe Harbor Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. The Company’s actual results may differ materially from those expressed in any forward-looking statements as a result of various factors and uncertainties. The reports filed by the Company with the Securities and Exchange Commission discuss these and other important factors and risks that may affect the Company’s business, results of operations and financial conditions. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Feng Zhou, Chief Executive Officer
Email: fzhou@sxtchina.com
FAQ
What does the 1-for-150 share consolidation mean for SXTC shareholders?
When will SXTC shares trade on a post-consolidation basis on Nasdaq?
How many SXTC Class A shares will be outstanding after the consolidation?
Will my SXTC stock held in a brokerage account be adjusted automatically?
How will outstanding SXTC options and warrants be affected by the consolidation?
